Living Cell Technologies in trading halt pending Parkinson's trial result

Living Cell Technologies in trading halt pending Parkinson's trial result
Paul McBeth
By Paul McBeth Nov. 9 (BusinessDesk) - ASX-listed Kiwi biotech firm Living Cell Technologies is in a trading halt until tomorrow when it expects to announce the results of a clinical trial testing its treatment for Parkinson's disease.  The Melbourne-based company's Phase IIb clinical trial was completed in April and it's been waiting for the results to be unblinded, which if successful would see Living Cell apply for provisional consent and launch its NTCELL treatment for Parkinson's in 2018. It today sought a halt in trading of its shar...